|
1
|
Yamamoto-Yamaguchi Y, Yamada K, Ishii Y,
Asahi KI, Tomoyasu S and Honma Y: Induction of the monocytic
differentiation of myeloid leukaemia cells by cotylenin A, a plant
growth regulator. Br J Haematol. 112:697–705. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yamada K, Honma Y, Asahi KI, Sassa T, Hino
KI and Tomoyasu S: Differentiation of human acute myeloid leukaemia
cells in primary culture in response to cotylenin A, a plant growth
regulator. Br J Haematol. 114:814–821. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Honma Y and Cotylenin A: Cotylenin A - a
plant growth regulator as a differentiation-inducing agent against
myeloid leukemia. Leuk Lymphoma. 43:1169–1178. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Honma Y, Ishii Y, Sassa T and Asahi K:
Treatment of human promyelocytic leukemia in the SCID mouse model
with cotylenin A, an inducer of myelomonocytic differentiation of
leukemia cells. Leuk Res. 27:1019–1025. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Honma Y and Akimoto M: Therapeutic
strategy using phenotypic modulation of cancer cells by
differentiation-inducing agents. Cancer Sci. 98:1643–1651. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Honma Y, Ishii Y, Yamamoto-Yamaguchi Y,
Sassa T and Asahi K: Cotylenin A, a differentiation-inducing agent,
and IFN-alpha cooperatively induce apoptosis and have an antitumor
effect on human non-small cell lung carcinoma cells in nude mice.
Cancer Res. 63:3659–3666. 2003.PubMed/NCBI
|
|
7
|
Honma Y, Kasukabe T, Yamori T, Kato N and
Sassa T: Antitumor effect of cotylenin A plus interferon-α:
Possible therapeutic agents against ovary carcinoma. Gynecol Oncol.
99:680–688. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sassa T, Tojyo T and Munakata K: Isolation
of a new plant growth substance with cytokinin-like activity.
Nature. 227:3791970. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kasukabe T, Okabe-Kado J, Kato N, Sassa T
and Honma Y: Effects of combined treatment with rapamycin and
cotylenin A, a novel differentiation-inducing agent, on human
breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res.
7:R1097–R1110. 2005. View
Article : Google Scholar
|
|
10
|
Ishii Y, Hori Y, Sakai S and Honma Y:
Control of differentiation and apoptosis of human myeloid leukemia
cells by cytokinins and cytokinin nucleosides, plant
redifferentiation-inducing hormones. Cell Growth Differ. 13:19–26.
2002.PubMed/NCBI
|
|
11
|
Niitsu N, Higashihara M and Honma Y: The
catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans
retinoic acid cooperatively induce granulocytic differentiation of
acute promyelocytic leukemia cells: Candidate drugs for
chemodifferentiation therapy against acute promyelocytic leukemia.
Exp Hematol. 30:1273–1282. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ikegame A, Ozaki S, Tsuji D, et al: Small
molecule antibody targeting HLA class I inhibits myeloma cancer
stem cells by repressing pluripotency-associated transcription
factors. Leukemia. 26:2124–2134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Quesada JR, Alexanian R, Hawkins M,
Barlogie B, Borden E, Itri L and Gutterman JU: Treatment of
multiple myeloma with recombinant alpha-interferon. Blood.
67:275–278. 1986.
|
|
14
|
Mandelli F, Avvisati G, Amadori S, et al:
Maintenance treatment with recombinant interferon alfa-2b in
patients with multiple myeloma responding to conventional induction
chemotherapy. N Engl J Med. 322:1430–1434. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marson A, Foreman R, Chevalier B, Bilodeau
S, Kahn M, Young RA and Jaenisch R: Wnt signaling promotes
reprogramming of somatic cells to pluripotency. Cell Stem Cell.
3:132–135. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
White EJ, Martin V, Liu JL, Klein SR, Piya
S, Gomez-Manzano C, Fueyo J and Jiang H: Autophagy regulation in
cancer development and therapy. Am J Cancer Res. 1:362–372.
2011.PubMed/NCBI
|
|
18
|
Xie R, Nguyen S, McKeehan WL and Liu L:
Acetylated microtubules are required for fusion of autophagosomes
with lysosomes. BMC Cell Biol. 11:892010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marimpietri D, Brignole C, Nico B, et al:
Combined therapeutic effects of vinblastine and rapamycin on human
neuroblastoma growth, apoptosis, and angiogenesis. Clin Cancer Res.
13:3977–3988. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH,
Cai Y, Chan SL and Yeo W: Sustained antitumor activity by
co-targeting mTOR and the microtubule with temsirolimus/vinblastine
combination in hepatocellular carcinoma. Biochem Pharmacol.
83:1146–1158. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Adiseshaiah PP, Clogston JD, McLeland CB,
et al: Synergistic combination therapy with nanoliposomal
C6-ceramide and vinblastine is associated with autophagy
dysfunction in hepatocarcinoma and colorectal cancer models. Cancer
Lett. 337:254–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hoang B, Benavides A, Shi Y, Frost P and
Lichtenstein A: Effect of autophagy on multiple myeloma cell
viability. Mol Cancer Ther. 8:1974–1984. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Agarwal JR and Matsui W: Multiple myeloma:
A paradigm for translation of the cancer stem cell hypothesis.
Anticancer Agents Med Chem. 10:116–120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Boucher K, Parquet N, Widen R, Shain K,
Baz R, Alsina M, Koomen J, Anasetti C, Dalton W and Perez LE:
Stemness of B-cell progenitors in multiple myeloma bone marrow.
Clin Cancer Res. 18:6155–6168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Spisek R, Kukreja A, Chen LC, et al:
Frequent and specific immunity to the embryonal stem
cell-associated antigen SOX2 in patients with monoclonal
gammopathy. J Exp Med. 204:831–840. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Leung-Hagesteijn C, Erdmann N, Cheung G,
Keats JJ, Stewart AK, Reece DE, Chung KC and Tiedemann RE:
Xbp1s-negative tumor B cells and pre-plasmablasts mediate
therapeutic proteasome inhibitor resistance in multiple myeloma.
Cancer Cell. 24:289–304. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kumar A, Galeb S and Djulbegovic B:
Treatment of patients with multiple myeloma: An overview of
systematic reviews. Acta Haematol. 125:8–22. 2011. View Article : Google Scholar
|
|
28
|
Suzuki K: Current therapeutic strategy for
multiple myeloma. Jpn J Clin Oncol. 43:116–124. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Galluzzi L, Vitale I, Abrams JM, et al:
Molecular definitions of cell death subroutines: Recommendations of
the Nomenclature Committee on Cell Death 2012. Cell Death Differ.
19:107–120. 2012. View Article : Google Scholar :
|
|
30
|
Oecking C, Eckerskorn C and Weiler EW: The
fusicoccin receptor of plants is a member of the 14-3-3 superfamily
of eukaryotic regulatory proteins. FEBS Lett. 352:163–166. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Molzan M, Kasper S, Röglin L, et al:
Stabilization of physical RAF/14-3-3 interaction by cotylenin A as
treatment strategy for RAS mutant cancers. ACS Chem Biol.
8:1869–1875. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kawakami K, Hattori M, Inoue T, et al: A
novel fusicoccin derivative preferentially targets hypoxic tumor
cells and inhibits tumor growth in xenografts. Anticancer Agents
Med Chem. 12:791–800. 2012. View Article : Google Scholar : PubMed/NCBI
|
